Valneva Inks COVID-19 Vaccine Supply Deal With EU

Valneva has struck a deal with the European Commission to supply up to 60 million doses of its inactivated COVID-19 vaccine, VLA2001, over a two-period.

Under the advance purchase agreement, an estimated 27 million doses are expected to be supplied next year and delivery is slated to begin in April 2022.

But, for this to happen, the shot must first receive authorization and be assessed by the European Medicines Agency, which will soon launch a rolling review.

Valneva reported positive phase 3 results last month, claiming that VLA2001 induced higher levels of neutralizing antibodies in adults 30 years and older than AstraZeneca’s shot in a head-to-head trial. The late-stage trial enrolled more than 4,000 adult participants across 26 UK sites.